Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CALY-002 by Novartis for Celiac Disease: Likelihood of Approval
CALY-002 is under clinical development by Novartis and currently in Phase I for Celiac Disease. According to GlobalData, Phase I...
Data Insights
CALY-002 by Novartis for Eosinophilic Esophagitis: Likelihood of Approval
CALY-002 is under clinical development by Novartis and currently in Phase I for Eosinophilic Esophagitis. According to GlobalData, Phase I...